Scott Smid

Dr Scott Smid

Senior Lecturer

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. Current interests include novel ligand development for binding and inhibiting pathological aggregating proteins such as beta-amyloid and alpha-synuclein, which are associated with Alzheimer's and Parkinson's disease.

Current projects for Honours, Masters, M.Phil or PhD candidates include:

1. Identifying novel cannabis phytochemicals with neuroprotective properties. This includes using neural stem cells and other neuronal cell populations to model neurotoxicity to dementia associated misfolding proteins such as amyloid beta and alpha-synuclein, related to Alzheimer's and Parkinson's disease. We recently identified a novel cannabis flavonoid with neuroprotective activity that could be used as a nutritional or nutraceutical supplement in ageing. We have also identified select terpenes found in cannabis that also share these neuroportective properties.

2. Identifying novel cannabis phytochemicals with gastroprotective properties. This projects looks at identifying novel cannabis phytochemicals with mucoprotective properties in the gut lining, related to inflammatory and other injurious conditions such as Crohn's disease and chemotherapy-induced mucositis.

3. Understanding cannabis-herb and cannabis-drug interactions. This is a molecular toxicology project aimed at understanding how cannabis and its components can influence metabolic pathways that may affect conventional medications or complementary medicines.

4. Identifying and Characterising novel marine-derived polyphenols with gastro- and neuro-protective properties. This is a collaboration with the Centre for Marine Bioproducts Development at Flinders University. For example, we have identified phlorotannins from brown macroalgae (seaweed) found along coastal regions in South Australia that have neuroprotective bioactivity.

    Expand

  • Journals
    Year Citation
    2021 Franco, G. D. R. R., Smid, S., & Viegas, C. (2021). Phytocannabinoids: General aspects and pharmacological potential in neurodegenerative diseases. Current Neuropharmacology, 19(4), 449-464.
    DOI Scopus1 WoS1
    2021 Shrestha, S., Zhang, W., & Smid, S. D. (2021). Phlorotannins: A review on biosynthesis, chemistry and bioactivity. Food Bioscience, 39, 100832-1-100832-11.
    DOI Scopus4 WoS4
    2020 Marsh, D. T., & Smid, S. D. (2020). Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents. AUSTRALIAN JOURNAL OF CHEMISTRY, 74(6), 388-404.
    DOI Scopus1 WoS1
    2020 Jovcevski, B., Das, S., Smid, S., & Pukala, T. L. (2020). Polyphenol honokiol and flavone 2′,3′,4′-trihydroxyflavone differentially interact with α-synuclein at distinct phases of aggregation. ACS Chemical Neuroscience, 11(24), 4469-4477.
    DOI Scopus1
    2020 Alghazwi, M., Charoensiddhi, S., Smid, S., & Zhang, W. (2020). Impact of Ecklonia radiata extracts on the neuroprotective activities against amyloid beta (Aβ<inf>1-42</inf>) toxicity and aggregation. Journal of Functional Foods, 68, 9 pages.
    DOI Scopus2 WoS4
    2020 Gunasegaran, B., Neilsen, P. M., & Smid, S. D. (2020). P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.. Toxicol In Vitro, 67, 104908.
    DOI Scopus1 WoS1 Europe PMC1
    2020 Shrestha, S., Zhang, W., Begbie, A. J., Pukala, T. L., & Smid, S. D. (2020). Ecklonia radiata extract containing eckol protects neuronal cells against Aβ1-42 evoked toxicity and reduces aggregate density.. Food Funct, 11(7), 6509-6516.
    DOI Scopus2 WoS3 Europe PMC1
    2019 Das, S., & Smid, S. D. (2019). Small molecule diketone flavorants diacetyl and 2,3-pentanedione promote neurotoxicity but inhibit amyloid β aggregation. Toxicology Letters, 300, 67-72.
    DOI Scopus2 WoS2 Europe PMC1
    2019 Alghazwi, M., Smid, S., Karpiniec, S., & Zhang, W. (2019). Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida. International Journal of Biological Macromolecules, 122, 255-264.
    DOI Scopus11 WoS14 Europe PMC8
    2019 Alghazwi, M., Smid, S., Musgrave, I., & Zhang, W. (2019). In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ₁−₄₂) toxicity and aggregation. Neurochemistry International, 124, 215-224.
    DOI Scopus33 WoS36 Europe PMC18
    2019 Li, X., Smid, S. D., Lin, J., Gong, Z., Chen, S., You, F., . . . Jin, X. (2019). Neuroprotective and anti-amyloid β effect and main chemical profiles of white tea: Comparison against green, oolong and Black tea. Molecules, 24(10), 1-15.
    DOI Scopus9 WoS4 Europe PMC3
    2019 Eggers, C., Fujitani, M., Kato, R., & Smid, S. (2019). Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone.. Biochemical pharmacology, 169, 113609.
    DOI Scopus13 WoS12 Europe PMC4
    2018 Alghazwi, M., Smid, S., & Zhang, W. (2018). In vitro protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (Aβ₁−₄₂) induced neurotoxicity in PC-12 cells. Neurotoxicology and Teratology, 68, 72-83.
    DOI Scopus5 WoS5 Europe PMC2
    2018 Das, S., Pukala, T., & Smid, S. (2018). Exploring the structural diversity in inhibitors of α-Synuclein amyloidogenic folding, aggregation, and neurotoxicity. Frontiers in Chemistry, 6(MAY), 181-1-181-12.
    DOI Scopus11 WoS13 Europe PMC5
    2018 Hofma, B., Wardill, H., Mavrangelos, C., Campaniello, M., Dimasi, D., Bowen, J., . . . Hughes, P. (2018). Colonic migrating motor complexes are inhibited in acute tri-nitro benzene sulphonic acid colitis. PLoS ONE, 13(6), e0199394-1-e0199394-15.
    DOI Scopus10 WoS8 Europe PMC7
    2017 Das, S., & Smid, S. (2017). Identification of dibenzyl imidazolidine and triazole acetamide derivatives through virtual screening targeting amyloid beta aggregation and neurotoxicity in PC12 cells. European Journal of Medicinal Chemistry, 130, 354-364.
    DOI Scopus11 WoS11 Europe PMC3
    2017 Marsh, D., Das, S., Ridell, J., & Smid, S. (2017). Structure-activity relationships for flavone interactions with amyloid β reveal a novel anti-aggregatory and neuroprotective effect of 2′,3′,4′-trihydroxyflavone (2-D08). Bioorganic and Medicinal Chemistry, 25(14), 3827-3834.
    DOI Scopus22 WoS23 Europe PMC6
    2017 Campaniello, M. A., Mavrangelos, C., Eade, S., Harrington, A. M., Blackshaw, L. A., Brierley, S. M., . . . Hughes, P. A. (2017). Acute colitis chronically alters immune infiltration mechanisms and sensory neuro-immune interactions.. Brain, Behavior, and Immunity, 60, 319-332.
    DOI Scopus11 WoS10 Europe PMC5
    2016 Gibson, R., Coller, J., Wardill, H., Hutchinson, M., Smid, S., & Bowen, J. (2016). Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Supportive Care in Cancer, 24(5), 2251-2258.
    DOI Scopus15 WoS15 Europe PMC4
    2016 Das, S., Stark, L., Musgrave, I., Pukala, T., & Smid, S. (2016). Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity. Food & Function, 7(2), 1138-1146.
    DOI Scopus37 WoS35 Europe PMC14
    2016 Safdari, B., Sia, T., Wattchow, D., & Smid, S. (2016). Effects of pro-inflammatory cytokines, lipopolysaccharide and COX-2 mediators on human colonic neuromuscular function and epithelial permeability. Cytokine, 83, 231-238.
    DOI Scopus11 WoS8 Europe PMC5
    2016 Alghazwi, M., Kan, Y., Zhang, W., Gai, W., Garson, M., & Smid, S. (2016). Neuroprotective activities of natural products from marine macroalgae during 1999–2015. Journal of Applied Phycology, 28(6), 3599-3616.
    DOI Scopus30 WoS32
    2014 Janefjord, E., Maag, J., Harvey, B., & Smid, S. (2014). Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cellular and Molecular Neurobiology, 34(1), 31-42.
    DOI Scopus66 WoS59 Europe PMC36
    2014 Harvey, B., Sia, T., Wattchow, D., & Smid, S. (2014). Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine, 65(2), 236-244.
    DOI Scopus19 WoS17 Europe PMC10
    2013 Wong, D., Musgrave, I., Harvey, B., & Smid, S. (2013). Açaí (Euterpe oleraceae Mart.) berry extract exerts neuroprotective effects against β-amyloid exposure in vitro. Neuroscience Letters, 556, 221-226.
    DOI Scopus29 WoS25 Europe PMC15
    2013 Harvey, B., Nicotra, L., Vu, M., & Smid, S. (2013). Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine (Online), 63(2), 209-217.
    DOI Scopus23 WoS20 Europe PMC18
    2013 Nicotra, L., Vu, M., Harvey, B., & Smid, S. (2013). Prostaglandin ethanolamides attenuate damage in a human explant colitis model. Prostaglandins & Other Lipid Mediators, 100(1), 22-29.
    DOI Scopus15 WoS15 Europe PMC9
    2012 Smid, S., Maag, J., & Musgrave, I. (2012). Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical. Food & Function: linking the chemistry and physics of food with health and nutrition, 3(12), 1242-1250.
    DOI Scopus46 WoS44 Europe PMC19
    2012 Harvey, B., Ohlsson, K., Maag, J., Musgrave, I., & Smid, S. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1), 138-146.
    DOI Scopus52 WoS47 Europe PMC29
    2012 Harvey, B., & Smid, S. (2012). The gastrointestinal endocannabinoid system in health and inflammation. Current Topics in Pharmacology, 16(1), 107-118.
    Scopus1
    2011 Harvey, B., Musgrave, I., Ohlsson, K., Fransson, A., & Smid, S. (2011). The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro. Food Chemistry, 129(4), 1729-1736.
    DOI Scopus35 WoS32 Europe PMC17
    2009 Smid, S. (2009). Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clinical Ophthalmology (online), 3(1), 663-670.
    DOI Scopus14 Europe PMC7
    2009 Smid, S., & Svensson, K. (2009). Inhibition of cyclooxygenase-2 and EP₁ receptor antagonism reduces human colonic longitudinal muscle contractility in vitro. Prostaglandins & Other Lipid Mediators, 88(3-4), 117-121.
    DOI Scopus11 WoS11 Europe PMC8
    2008 Smid, S. (2008). Gastrointestinal endocannabinoid system: Multifaceted roles in the healthy and inflamed intestine. Clinical and Experimental Pharmacology and Physiology, 35(11), 1383-1387.
    DOI Scopus13 WoS11 Europe PMC8
    2007 Smid, S., Bjorklund, C., Svensson, K., Heigis, S., & Revesz, A. (2007). The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. European Journal of Pharmacology, 575(1-3), 168-176.
    DOI Scopus23 WoS21 Europe PMC13
    2006 Hinds, N., Ullrich, K., & Smid, S. (2006). Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. British Journal of Pharmacology, 148(2), 191-199.
    DOI Scopus48 WoS46 Europe PMC40
    2005 Smith, A., & Smid, S. (2005). Impaired capsaicin and neurokinin-evoked colonic motility in inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 20(5), 697-704.
    DOI Scopus26 WoS24 Europe PMC21
    2002 Lehmann, A., Blackshaw, L., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology, 123(4), 1129-1134.
    DOI Scopus84 WoS64 Europe PMC49
    2002 Lehmann, A., Blackshaw, L., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (vol 123, pg 1129, 2002). GASTROENTEROLOGY, 123(6), 2162-2163.
    2002 Lehmann, A., Blackshaw, L. A., Branden, L., Carlsson, A., Jensen, J., Nygren, E., & Smid, S. D. (2002). Erratum: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs (Gastroenterology (2002) 123 (1129-1134)). Gastroenterology, 123(6), 2162-2163.
    DOI
    2001 Smid, S., Young, R., Isaacs, N., & Blackshaw, L. (2001). GABABR expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. American Journal of Physiology - Gastrointestinal and Liver Physiology, 281(6), G1494-G1501.
    DOI Scopus61 WoS46 Europe PMC33
    2001 Smid, S., & Blackshaw, L. (2001). GABA(B) receptors inhibit vagal afferent mechanoreceptor responses to gastric distension.. GASTROENTEROLOGY, 120(5), A5-A6.
    2000 Blackshaw, L., Smid, S., Dent, J., & O'Donnell, T. (2000). GABAB receptor-mediated effects on vagal pathways to the lower oesophageal sphincter and heart. British Journal of Pharmacology, 130(2), 279-288.
    DOI Scopus43 WoS35 Europe PMC30
    2000 Staunton, E., Smid, S., Dent, J., & Blackshaw, L. (2000). Triggering of transient LES relaxations in ferrets: role of sympathetic pathways and effects of baclofen. American Journal of Physiology-Gastrointestinal and Liver Physiology, 279(1 42-1), G157-G162.
    DOI Scopus43 WoS33 Europe PMC26
    2000 Blackshaw, L., Page, A., Smid, S., Dent, J., & Lehmann, A. (2000). GABAB receptors - peripheral and central targets for controlling gastroesophageal reflux. Current Opinion in Central & Peripheral Nervous System Investigational Drugs, 2(3), 333-343.
    Scopus6
    2000 Smid, S., & Blackshaw, L. (2000). Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus. Gut, 46(6), 756-761.
    DOI Scopus18 WoS15 Europe PMC10
    2000 Smid, S., & Blackshaw, L. (2000). Vagal neurotransmission to the ferret lower oesophageal sphincter: inhibition via GABAB receptors. British Journal of Pharmacology, 131(3), 624-630.
    DOI Scopus25 WoS21 Europe PMC16
    2000 Smid, S., & Blackshaw, L. (2000). Vagal ganglionic and nonadrenergic noncholinergic neurotransmission to the ferret lower oesophageal sphincter. Autonomic Neuroscience-Basic & Clinical, 86(1-2), 30-36.
    DOI Scopus6 WoS5 Europe PMC5
    1998 Smid, S. D., Page, A. J., O'Donnell, T., Langman, J., Rowland, R., & Blackshaw, L. A. (1998). Oesophagitis-induced changes in capsaicin-sensitive tachykininergic pathways in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(5), 403-411.
    DOI Scopus14 WoS10 Europe PMC10
    1998 Smid, S. D., Lynn, P. A., Templeman, R., & Blackshaw, L. A. (1998). Activation of non-adrenergic non-cholinergic inhibitory pathways by endogenous and exogenous tachykinins in the ferret lower oesophageal sphincter. Neurogastroenterology and Motility, 10(2), 149-156.
    DOI Scopus14 WoS14 Europe PMC9
    1995 Smid, S., Frewin, D., Wyartt, C., & Head, R. (1995). Functional tolerance to a-adrenergic receptor blockade in the spontaneously hypertensive rat highlights the multi-functional role of vascular angiotensin II in the development of hypertension. Journal of Vascular Research, 32(4), 247-253.
    DOI Scopus4 WoS4 Europe PMC2
    1993 Jonsson, J., Smid, S., Frewin, D., & Head, R. (1993). Angiotensin II-mediated facilitation of sympathetic neurotransmission in the spontaneously hypertensive rat is not associated with neuronal uptake of the peptide. Journal of Cardiovascular Pharmacology, 22(5), 750-753.
    DOI Scopus16 WoS14 Europe PMC10

  • Book Chapters
    Year Citation
    2014 Das, S., & Smid, S. (2014). The Antiaggregative, Antiamyloid Properties of Bioactive Polyphenols in the Treatment of Alzheimer's Disease. In R. Watson (Ed.), Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy (pp. 73-76). United Kingdom: Academic Press.
    DOI Scopus1
    2013 Smid, S., & Musgrave, I. (2013). Dietary polyphenols as inhibitors of Β-amyloid-evoked neurotoxicity: implications for the treatment of Alzheimer's disease. In J. Sun, K. Prasad, A. Ismail, B. Yang, X. You, & L. Li (Eds.), Polyphenols: Chemistry, Dietary Sources and Health Benefits (1 ed., pp. 521-538). United States: Nova Science Publishers.
    2009 Smid, S. (2009). Neuronal mechanosensitivity in the gastrointestinal tract. In A. Kamkin, I. Kiseleva, N. Tavernarakis, & P. Persson (Eds.), Mechanosensitivity of the nervous system (pp. 87-106). Russia: Springer.
    DOI

  • Conference Papers
    Year Citation
    2015 Smid, S., Das, S., Musgrave, I., & Pukala, T. (2015). Bioactive polyphenol interactions with beta amyloid: a comparison of binding, fibril inhibition and neuroprotection. In JOURNAL OF NEUROCHEMISTRY Vol. 134 (pp. 363-364). Cairns, AUSTRALIA: WILEY-BLACKWELL.

  • Conference Items
    Year Citation
    2016 Campaniello, M., Mavrangelos, C., Dimasi, D., Hofma, B., Eade, S., Smid, S., . . . Hughes, P. A. (2016). Innate cell infiltration during acute TNBS colitis alters enteric nerve activity. Poster session presented at the meeting of Gastroenterology. San Diego, CA: Elsevier Inc..
    DOI
    2011 Smid, S., Salem, A., & Musgrave, I. (2011). Blended learning approaches to practical teaching in pharmacology: the best of both worlds?. Poster session presented at the meeting of Transformation. Adelaide, Australia.
    2010 Salem, A., Smid, S., Musgrave, I., & Carrington, A. (2010). Development and integration of web-based pharmacology e-resources designed to provide immediate feedback and interactive help. Poster session presented at the meeting of The Education Research Group of Adelaid. Adelaide, Australia: The University of Adelaide.
Grants and Funding
Research Support and Scholarship
2021 Co-Investigator. Exploring the use of personalised CBD/THC dosing to prevent common and impactful symptoms of treatment in advanced cancer. The CANnabinoids for CANcer Therapy (CANCAN) Clinical Trial: Medical Research Futures Fund, Department of Health, Australian Goverment. $AUD $1.5M

2019

 Principal Investigator. Australia Japan Foundation Award, Dept Foreign Affairs and Trade. Enabling technologies in Personalised and Precision Medicine.

$AUD 38,600
2018 JSPS Invitational Fellowship, Nagoya University. Development of Super-efficient Screening Technologies for Neural Cell Regulatory Products.

¥JPY

342,000
2018 Principal Investigator. Faculty Research Infrastructure Award. The University of Adelaide. AUD $17,000
2017-18 Principal Investigator. Faculty Research Development Award (with Prof Kato, Nagoya University and Dr Ian Musgrave). Novel neuroprotective agents targeting beta amyloid. The University of Adelaide. AUD $15,500
2013-15 Co-Investigator (with Ian Musgrave, Louise O’Keefe and Tara Pukala). 'Structure function relationships of anti-amyloid drugs: verification in an in-vivo model.' lnterdisciplinary Research Fund Grant, The University of Adelaide. AUD $21,000
2011-13 Principal Investigator. (Associate Investigator: Dr Rachel Gibson). Validation of an ex vivo human colonic mucosal explant colitis model. MAWA Trust Research Grant. AUD $28,122
2010-12 Principal Investigator Broad Medical Research Program, United States (IBD-0268R). Functional Expression of the Endocannabinoid System in Inflammatory Bowel Disease. USD $130,000
Teaching and Course Coordination
2006-present The University of Adelaide: Course Coordinator - PHARM 3102 Drug Discovery & Development; HLTH SC 2100 Fundamentals of Human Nutrition. Courses taught: Pharmacology 2100/2200 (Level 2 B.Hlth.Sci, B. Pharm. Eng.). Pharmacology for Nursing (Level 1&2, Bachelor of Nursing). PHARM 3101, 3102, 3103, HLTH SC 2100, 2103, 2104, 3100. Higher Degree by Research: Discipline Coordinator
    Expand

  • Current Higher Degree by Research Supervision (University of Adelaide)
    Date Role Research Topic Program Degree Type Student Load Student Name
    2021 Principal Supervisor Bioactivity characterization of novel cannabis phytochemicals Master of Philosophy (Medical Science) Master Full Time Mr John Staton Laws
    2019 Principal Supervisor Neuroprotective Bioactivity of Marine and Plant Based Polyphenols Doctor of Philosophy Doctorate Full Time Mr Srijan Shrestha
    2017 Principal Supervisor Bioactivity of Phytochemicals in Neurodegenerative and Inflammatory Diseases Doctor of Philosophy Doctorate Full Time Mr Dylan Thomas Marsh

  • Past Higher Degree by Research Supervision (University of Adelaide)
    Date Role Research Topic Program Degree Type Student Load Student Name
    2016 - 2020 Co-Supervisor Visualising Intestinal Inflammation and Fibrosis using Zirconium-89 Labelled Antibodies in a Preclinical Model of Inflammatory Bowel Disease Doctor of Philosophy Doctorate Full Time Miss Nicole Dmochowska
    2015 - 2018 Principal Supervisor Small molecular inhibitors of Amyloid beta and alpha Synuclein amyloidogenic aggregation, toxicity and in silico design of amyloid-binding ligands Doctor of Philosophy Doctorate Full Time Mrs Sukanya Das
    2010 - 2014 Principal Supervisor The Effect of Cannabinoids on Cytokine Evoked Human Colonic Mucosal Damage and Caco-2 Epithelial Permeability Doctor of Philosophy Doctorate Full Time Mr Benjamin Harvey
  • Position: Senior Lecturer
  • Phone: 83135287
  • Email: scott.smid@adelaide.edu.au
  • Fax: 8224 0685
  • Campus: North Terrace
  • Building: Helen Mayo North, floor 5
  • Room: 5 31
  • Org Unit: Medical Sciences
Connect With Me
External Profiles